Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Carboplatin (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 15 Aug 2022 Status changed from suspended to completed.
- 07 Dec 2020 Planned primary completion date changed from 1 Jun 2020 to 1 May 2021.
- 21 Sep 2020 Results (n=32; as of May 2020) presented at the 45th European Society for Medical Oncology Congress.